Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
The Journal of Allergy and Clinical Immunology. in Practice|May 14, 2022
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5Marc E Rothenberg, Florence Roufosse, Stanislas Faguer, et al.
ERJ Open Research|May 5, 2022
Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumabIan D Pavord, Roland Buhl, Monica Kraft, et al.
Current Medical Research and Opinion|May 1, 2010
Effect of increased body mass index on asthma risk, impairment and response to asthma controller therapy in African AmericansCarlos A Camargo, E Rand Sutherland, William Bailey, et al.
Pediatric Pulmonology|September 11, 2019
Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthmaAtul Gupta, Isabelle Pouliquen, Daren Austin, et al.
The Journal of Allergy and Clinical Immunology|August 20, 2019
Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotypeAtul Gupta, Masanori Ikeda, Bob Geng, et al.
Clinical Therapeutics|August 25, 2016
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb StudyNjira Lugogo, Christian Domingo, Pascal Chanez, et al.
Respiratory Medicine|November 22, 2019
Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthmaFrank C Albers, Christopher Licskai, Pascal Chanez, et al.
The Journal of Allergy and Clinical Immunology|October 13, 2006
Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthmaEugene R Bleecker, Steven W Yancey, Leslie A Baitinger, et al.
Respiratory Medicine|January 22, 2008
Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once dailyEdward M Kerwin, Robert A Nathan, Eli O Meltzer, et al.
The Journal of Allergy and Clinical Immunology|January 18, 2003
Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice dailyWilliam Busse, Steven M Koenig, John Oppenheimer, et al.
Pageof 7